{
Pfizer Inc.

Companies

}
two healthcare dividend stocks to consider during market volatility
As 2024 closes with the S&P 500 achieving a 25% return, investors are advised to consider defensive strategies amid potential market volatility. AbbVie, with a strong dividend yield and promising drug sales growth, and Pfizer, offering a high yield and new growth drivers, are highlighted as solid healthcare sector investments for uncertain times. Both companies are well-positioned for continued success as they enter 2025.
The Motley Fool
United States Dollar ABBVIE Pfizer Inc. USA
Healthcare, Market Report
12:50 22.12.2024
navigating a pricey stock market strategies for 2025 investment success
Wall Street is experiencing one of its priciest stock markets in history, with the S&P 500's Shiller P/E ratio nearing 39, significantly above the historical average of 17.19. This elevated valuation raises concerns about potential volatility and declines in 2025, prompting a strategy of holding 15% to 30% of portfolios in cash to capitalize on future buying opportunities. Historical trends indicate that when the Shiller P/E exceeds 30, significant market corrections often follow.
The Motley Fool
United States Dollar Pfizer Inc.
Finance & Economy, Market Report
11:06 21.12.2024
global uveitis treatment market poised for significant growth by 2032
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
openPR.com
Pfizer Inc. Bayer AG Novartis AG Regeneron Pharmaceuticals, Inc. Merck & Co., Inc. CIPLA LTD Lupin Limited Hoffmann-La Roche AG Bausch Health Companies Inc. BIOGEN ABBVIE Alimera Sciences Inc. SAU ISR FRA RUS DEU TWN ARG ARE AUT TUR SGP NZL CHL USA BRA CAN ITA JPN IDN GBR ESP IND MYS COL AUS THA EGY VNM KOR PHL CHN ZAF MEX Nidhi Bhavsar Show more
Healthcare, Market Report
20:41 19.12.2024
China's ensartinib gains FDA approval for lung cancer treatment
Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
Fierce Pharma
United States Dollar Chinese Yuan Swiss Franc Japanese Yen AstraZeneca PLC Hoffmann-La Roche AG Pfizer Inc. Novartis AG CHN USA JPN Show more
Healthcare, Market Report
16:20 19.12.2024
UBS maintains neutral rating on Pfizer amid lung cancer study concerns
UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $31. The decision to terminate the lung cancer study with Sasanlimab is attributed to strategic reasons, though high dropout rates raise concerns, particularly regarding the ongoing phase III bladder cancer study.
boerse.de
United States Dollar Pfizer Inc. USA Warren Buffett Trung Huynh
Healthcare, Market Report
08:26 19.12.2024
pfizer receives neutral rating from ubs amid diverse product portfolio
Pfizer Inc., the leading pharmaceutical group, has received a Neutral rating from UBS. Its net sales are primarily driven by primary care products (52.3%), followed by specialty care (25.6%) and oncology (19.9%). Geographically, sales are distributed with 42.3% in the U.S., 21.9% in Europe, and 33.8% in other regions.
MarketScreener
United States Dollar Pfizer Inc. USA
Healthcare, Market Report
08:13 19.12.2024
stocks decline as dow experiences longest losing streak since 1978
U.S. stocks fell on Tuesday, with the Dow experiencing its longest losing streak since February 1978, dropping for the ninth consecutive session. Investors are cautious ahead of the Federal Reserve's policy announcement, anticipating a 25 basis point rate cut, while economic data shows solid consumer spending. The S&P 500 and Nasdaq also declined, though Tesla's stock rose significantly after a price target increase.
Reuters
United States Dollar Tesla, Inc. Pfizer Inc. USA Jerome Powell Richard Chang Jason Ware Lisa Pauline Mattackal Brendan Mcdermid Purvi Agarwal Show more
Finance & Economy, Market Report
22:24 17.12.2024
dow jones faces longest losing streak since 1970s amid economic concerns
Investors are concerned that Trump's potential trade tariffs could exacerbate inflation, as retail sales rose 0.7% in November. The Dow Jones is on track for its longest losing streak since the 1970s, while Nvidia faces challenges with thermal issues in its chips, impacting its stock. Tesla continues to rise, with analysts projecting a bullish outlook for 2025.
Investor's Business Daily
United States Dollar Berkshire Hathaway Inc. Pfizer Inc. Heico Corp Alphabet Inc. Tesla, Inc. Broadcom Inc. Amazon.com, Inc. Metagenomi, Inc. FedEx Corp Lennar Corp NIKE, Inc. Microsoft Corp Apple Inc. NVIDIA Corporation USA Warren Buffett Dan Ives Timothy Arcuri Ming-chi Kuo Donald Trump Show more
Finance & Economy, Market Report
18:30 17.12.2024
stock market retreats as nvidia falters and bitcoin hits new high
U.S. stock indexes pulled back, with the S&P 500 down 0.4% and Nvidia's stock falling 1.2%, marking its eighth loss in nine days. Despite this, the S&P 500 is up nearly 27% for the year, buoyed by strong economic resilience and expectations of favorable policies from President-elect Trump. Bitcoin briefly surpassed $108,000 before retreating to around $106,500.
The Blade
United States Dollar Japanese Yen British Pound Sterling Bristol-Myers Squibb Co Broadcom Inc. Pfizer Inc. NVIDIA Corporation USA GBR JPN Michael Hartnett Chris Larkin Show more
Finance & Economy, Market Report
17:40 17.12.2024
UBS Maintains Neutral Rating on Pfizer with 31 Dollar Price Target
UBS has maintained a 'Neutral' rating for Pfizer, setting a price target of 31 US dollars. Analyst Trung Huynh noted that the pharmaceutical company's outlook for 2025 did not present any surprises in his initial reaction.
MarketScreener
United States Dollar Pfizer Inc. USA Trung Huynh
Healthcare, Market Report
17:33 17.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.